Despite strong revenue growth, Baxter struggles with profitability and high long-term debt. Click here to read why BAX stock ...

Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, such as inflation and weak medical utilization trends. With medical utilization rising, ...

Baxter might have faced fourth-quarter hurdles from Hurricane Helene. However, it expects growth in infusion therapies, ...

Baxter International’s longtime CEO and board chair, José Almeida, is stepping down and retiring, effective immediately, the ...

IV treatment is one of the most traditionalist and wide-spread treatments provided to the 90% of hospitalised patients, yet, recent supply challenges like the Baxter IV fluids crisis have shown ...

Baxter's Q3 beat was driven by strong demand for Medical Products & Therapies, including the successful U.S. launch of the Novum IQ infusion pump. For fiscal 2024, analysts expect BAX to report ...

b IVP = i.v. push, IV = i.v. infusion over at least 60 minutes, SP = syringe-pump infusion over less than 40 minutes.